Company intelligence / Profile preview

IDAC Theranostics

Ownership: Private
Development stage: Other

Overview

IDAC Theranostics is conducting a Phase 1 clinical trial of IT1208, a humanized anti-CD4 monoclonal antibody for the treatment of solid tumors, with preclinical data supporting immunomodulatory antitumor activity through depletion of CD4+ T cells; additional research is directed toward HIV eradication.[4]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

IT1208

Unknown

Partnerships

Kyowa Hakko Kirin (licensor of anti-CD4 antibody technology)ONO Pharmaceutical (option and evaluation/licensing agreement for IT1208)

Beyond the preview

Go deeper on IDAC Theranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDAC Theranostics.